Pharvaris (NASDAQ:PHVS) Coverage Initiated at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Pharvaris (NASDAQ:PHVS - Free Report) in a research note published on Tuesday morning, MarketBeat reports. The firm issued an overweight rating and a $28.00 target price on the stock. Cantor Fitzgerald also issued estimates for Pharvaris' FY2025 earnings at ($3.31) EPS.

Separately, JMP Securities lifted their price objective on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research report on Friday, January 31st.

Pharvaris Trading Up 2.9 %

PHVS stock traded up $0.52 during midday trading on Tuesday, reaching $18.37. 20,504 shares of the company's stock traded hands, compared to its average volume of 73,362. The stock's 50-day moving average is $15.04 and its 200 day moving average is $18.06. The stock has a market cap of $960.57 million, a P/E ratio of -6.56 and a beta of -2.84. Pharvaris has a 52-week low of $11.51 and a 52-week high of $25.50.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Monday, April 7th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.06. As a group, research analysts expect that Pharvaris will post -2.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Palumbo Wealth Management LLC boosted its stake in shares of Pharvaris by 38.0% in the first quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company's stock worth $221,000 after acquiring an additional 3,881 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Pharvaris by 30.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company's stock worth $1,222,000 after purchasing an additional 14,838 shares in the last quarter. Woodline Partners LP bought a new position in Pharvaris in the 4th quarter worth approximately $853,000. Soleus Capital Management L.P. grew its holdings in Pharvaris by 36.2% during the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock valued at $15,617,000 after buying an additional 216,483 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Pharvaris during the fourth quarter valued at approximately $152,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.